Chengdi Wang

6.3k total citations · 3 hit papers
102 papers, 2.7k citations indexed

About

Chengdi Wang is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Chengdi Wang has authored 102 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Pulmonary and Respiratory Medicine, 38 papers in Radiology, Nuclear Medicine and Imaging and 26 papers in Molecular Biology. Recurrent topics in Chengdi Wang's work include Lung Cancer Diagnosis and Treatment (30 papers), Radiomics and Machine Learning in Medical Imaging (29 papers) and Lung Cancer Treatments and Mutations (23 papers). Chengdi Wang is often cited by papers focused on Lung Cancer Diagnosis and Treatment (30 papers), Radiomics and Machine Learning in Medical Imaging (29 papers) and Lung Cancer Treatments and Mutations (23 papers). Chengdi Wang collaborates with scholars based in China, United States and Hong Kong. Chengdi Wang's co-authors include Weimin Li, Jun Shao, Shengtao Zhou, Jingwei Li, Zhoufeng Wang, Yuting Jiang, Kang Zhang, Yizhou Yu, Min Zhu and Jiechao Ma and has published in prestigious journals such as Nature Medicine, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Chengdi Wang

96 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

COVID-19 in early 2021: current status and looking forward

2021 197 citations Chengdi Wang, Zhoufeng Wang et al. Signal Transduction and Targeted Therapy profile →
A transformer-based representation-learning model with unified processing of multimodal input for clinical diagnostics

2023 168 citations Yizhou Yu, Chengdi Wang et al. profile →
The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID

2023 60 citations Jiechao Ma, Jun Shao et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chengdi Wang China	28	897	729	725	515	456	102	2.7k
Hong Zhang China	27	724 0.8×	858 1.2×	609 0.8×	591 1.1×	380 0.8×	214	2.9k
Honggang Yu China	30	508 0.6×	720 1.0×	561 0.8×	700 1.4×	369 0.8×	109	2.7k
Christine B. Peterson United States	27	523 0.6×	1.2k 1.6×	513 0.7×	309 0.6×	178 0.4×	173	2.8k
Sui Peng China	37	665 0.7×	1.4k 2.0×	597 0.8×	812 1.6×	808 1.8×	122	4.0k
Tingting Jiang China	26	441 0.5×	1.4k 1.9×	424 0.6×	632 1.2×	590 1.3×	128	3.2k
Hyungjin Kim South Korea	33	1.5k 1.7×	769 1.1×	1.9k 2.6×	586 1.1×	133 0.3×	185	4.4k
Jing Cai China	30	393 0.4×	1.2k 1.6×	247 0.3×	517 1.0×	714 1.6×	99	2.8k
Jingping Yuan China	26	420 0.5×	1.2k 1.6×	232 0.3×	768 1.5×	788 1.7×	121	3.2k
Jia Wu United States	28	626 0.7×	349 0.5×	1.4k 1.9×	404 0.8×	299 0.7×	98	2.4k

Countries citing papers authored by Chengdi Wang

Since Specialization

Citations

This map shows the geographic impact of Chengdi Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengdi Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengdi Wang more than expected).

Fields of papers citing papers by Chengdi Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengdi Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengdi Wang. The network helps show where Chengdi Wang may publish in the future.

Co-authorship network of co-authors of Chengdi Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Chengdi Wang. A scholar is included among the top collaborators of Chengdi Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengdi Wang. Chengdi Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lu, Yuxing, Yunfang Yu, Bojiang Chen, et al.. (2025). AI-enabled molecular phenotyping and prognostic predictions in lung cancer through multimodal clinical information integration. Cell Reports Medicine. 6(7). 102216–102216. 2 indexed citations

Wang, Chengdi, Jingwei Li, Jingyao Chen, et al.. (2025). Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer. Nature Communications. 16(1). 1477–1477. 13 indexed citations

Xu, Xiuyuan, Jun Shao, Jixiang Guo, et al.. (2024). Deep learning for precise diagnosis and subtype triage of drug‐resistant tuberculosis on chest computed tomography. SHILAP Revista de lepidopterología. 5(3). e487–e487. 12 indexed citations

Ma, Jiechao, et al.. (2024). A multimodal integration pipeline for accurate diagnosis, pathogen identification, and prognosis prediction of pulmonary infections. The Innovation. 5(4). 100648–100648. 14 indexed citations

Lyu, Mengyuan, Yanbing Zhou, Weelic Chong, et al.. (2023). From tuberculosis bedside to bench: UBE2B splicing as a potential biomarker and its regulatory mechanism. Signal Transduction and Targeted Therapy. 8(1). 82–82. 8 indexed citations

Hu, Zelin, Ya Zhang, Wenhan Yu, et al.. (2023). Transient receptor potential ankyrin 1 (TRPA1) modulators: Recent update and future perspective. European Journal of Medicinal Chemistry. 257. 115392–115392. 18 indexed citations

Jin, Jing, Chengdi Wang, Pengwei Ren, et al.. (2023). Common nutritional/inflammatory indicators are not effective tools in predicting the overall survival of patients with small cell lung cancer undergoing first-line chemotherapy. Frontiers in Oncology. 13. 1211752–1211752. 3 indexed citations

Li, Peiyi, Yajuan Zhu, Yaqiang Wang, et al.. (2023). Impact of the COVID‐19 pandemic on cancer healthcare utilization in southwestern China to March 2021. Cancer Medicine. 12(12). 13821–13833. 4 indexed citations

Yuan, Jiani, Jiaxing Wang, Xiaoxue Li, et al.. (2023). Amphiphilic small molecule antimicrobials: From cationic antimicrobial peptides (CAMPs) to mechanism-related, structurally-diverse antimicrobials. European Journal of Medicinal Chemistry. 262. 115896–115896. 17 indexed citations

10.

Zhang, Siqi, Xiaohong Liu, Lixin Zhou, et al.. (2023). Intelligent prognosis evaluation system for stage I-III resected non-small-cell lung cancer patients on CT images: a multi-center study. EClinicalMedicine. 65. 102270–102270. 3 indexed citations

11.

Yang, Shengjie, et al.. (2023). Predicting EGFR Mutation Status Using Multi-View Transformer. 538–545. 1 indexed citations

12.

Qiu, Rong, Jingwei Li, Yuxuan Xiao, et al.. (2021). The therapeutic effect and safety of the drugs for COVID-19. Medicine. 100(16). e25532–e25532. 3 indexed citations

13.

Wang, Chengdi, Zhoufeng Wang, Guangyu Wang, et al.. (2021). COVID-19 in early 2021: current status and looking forward. Signal Transduction and Targeted Therapy. 6(1). 114–114. 197 indexed citations breakdown →

14.

Wang, Zhoufeng, Zhe Li, Kun Zhou, et al.. (2021). Deciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing. Nature Communications. 12(1). 6500–6500. 98 indexed citations

15.

Wang, Chengdi, Jingwei Li, Qiran Zhang, et al.. (2021). The landscape of immune checkpoint inhibitor therapy in advanced lung cancer. BMC Cancer. 21(1). 968–968. 16 indexed citations

16.

Wang, Chengdi, Jun Shao, Junwei Lv, et al.. (2021). Deep learning for predicting subtype classification and survival of lung adenocarcinoma on computed tomography. Translational Oncology. 14(8). 101141–101141. 44 indexed citations

17.

Wang, Chengdi, Yuxuan Wu, Jun Shao, Dan Liu, & Weimin Li. (2020). Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer. BMC Cancer. 20(1). 150–150. 61 indexed citations

18.

Cheng, Jie, Yangping Wu, Yuxi Wang, et al.. (2017). Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design. Biochemical and Biophysical Research Communications. 495(1). 185–188. 6 indexed citations

19.

Liu, Qianqian, Wenzhang Li, Xinmiao Du, et al.. (2017). Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. Scientific Reports. 7(1). 1090–1090. 68 indexed citations

20.

Li, Taiming, et al.. (2016). Association between the cytotoxic T-lymphocyte antigen 4-318C/T polymorphism and malignant tumor risk. Biomedical Reports. 5(1). 93–100. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact